Beijing Okeanos Technology is a technology company.
Beijing Okeanos Technology has raised $22.0M across 1 funding round.
Beijing Okeanos Technology has raised $22.0M in total across 1 funding round.
Beijing Okeanos Technology is a high-tech company specializing in the development and production of special biochemical reagents and pharmaceutical intermediates primarily for the life sciences sector. It serves pharmaceutical companies, research institutions, and biotech firms by providing custom synthesis and manufacturing solutions that address complex chemical and biological challenges in drug development and life science research. The company has demonstrated steady growth by expanding its R&D capabilities and manufacturing scale to meet increasing demand in the pharmaceutical outsourcing market[1][2][4][6].
Founded in 2006, Beijing Okeanos Technology emerged to fill a niche in the life sciences supply chain by offering specialized chemical reagents and intermediates that are critical for drug discovery and production. The founders leveraged expertise in chemistry and biotechnology to build a company focused on innovation and quality. Early traction came from establishing two factories and an R&D center, enabling the company to deliver tailored solutions and build long-term partnerships with global pharmaceutical clients[1][2][6].
Beijing Okeanos Technology rides the growing trend of pharmaceutical outsourcing and the increasing complexity of drug molecules requiring specialized intermediates. The timing is favorable due to the global expansion of biotech research and the pharmaceutical industry's shift toward external partnerships for cost efficiency and innovation speed. By providing critical chemical building blocks and reagents, Okeanos supports the broader ecosystem of drug discovery and development, enabling faster and more efficient creation of new therapies.
Looking ahead, Beijing Okeanos Technology is well-positioned to capitalize on the rising demand for complex pharmaceutical intermediates driven by advances in biologics and personalized medicine. Trends such as increased R&D outsourcing, stricter regulatory requirements, and the need for innovative chemical solutions will shape its growth trajectory. The company’s continued investment in R&D and manufacturing capacity will likely enhance its influence as a key supplier in the global life sciences supply chain, reinforcing its role as a vital enabler of pharmaceutical innovation.
Beijing Okeanos Technology has raised $22.0M in total across 1 funding round.
Beijing Okeanos Technology's investors include Qiming Venture Partners.
Beijing Okeanos Technology has raised $22.0M across 1 funding round. Most recently, it raised $22.0M Series B in October 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2021 | $22.0M Series B | Qiming Venture Partners |